If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 ...

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing ...

Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for cash-paying patients in the United States.

We’ll be back on Monday morning with more fresh content!

The short-term study is believed to be the first to evaluate both interventions combined for people with mental illness.

Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer ...

AstraZeneca will launch a new online platform to make Airsupra, as well as Farxiga and Flumist, available for home delivery ...

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more ...

The expiration of ACA tax credits threatens $32 billion in healthcare revenue, risking coverage for millions and increasing ...

Evkeeza is now approved for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients as young as 1 year ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

Recent analysis reveals Medicaid's impact on mortality, highlighting the need for diverse research methods to inform policy ...